Keyword Search
Sessions Were Renumbered as of May 19.
Legend:
CC-W = McCormick Place Convention Center, West Building, CC-N = McCormick Place Convention Center, North Building
H = Hilton Chicago, UC= Conference Chicago at University Center
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: historical returned 23 record(s)
|
|
Sunday, 07/31/2016
|
Analysis of Longitudinal Multi-Sequence MRI in Multiple Sclerosis
Elizabeth M. Sweeney, Johns Hopkins Bloomberg School of Public Health ; Russell Shinohara, University of Pennsylvania; John Muschelli, The Johns Hopkins University; Daniel Reich , National Institute of Neurological Disorders and Stroke; Ciprian Crainiceanu, The Johns Hopkins University; Jonathan Gellar, Mathematica Policy Research; Philip Reiss, New York University/University of Haifa; Ani Eloyan, Brown University
|
Incorporation of Historical Information in Bayesian Analysis of Crossover Medical Device Clinical Trials
Youssef Toubouti, Johnson & Johnson Vision Care; Xiwei Chen, Johnson & Johnson Vision Care
2:35 PM
|
Bayesian Clinical Trial Design for Survival Studies with Historical Study Data Under a Proportional Hazards Assumption
Matthew Psioda, The University of North Carolina at Chapel Hill; Joseph G. Ibrahim, The University of North Carolina at Chapel Hill
4:35 PM
|
Bayesian Methods in Phase 3 HCV Trials: Borrowing Historical Control Arm Data
Ran Liu, AbbVie; Qi Tang, AbbVie; Martin King, AbbVie; Bo Fu, AbbVie; Sandra Lovell, AbbVie; Alan Hartford, AbbVie
5:35 PM
|
|
Monday, 08/01/2016
|
An Extension of Clinical Trial Assurance to a Setting of Multiple Unknown Parameters in a Single-Arm Binomial Trial
Yizhou Jiang, Kite Pharma; Lynn Navale, Kite Pharma; Allen Xue, Kite Pharma
|
Bayesian Noncomparative Designs to Account for Uncertainty in Historical Response Rates
Francesca Matano, Carnegie Mellon University; Valeria Sambucini, University of Rome "La Sapienza"
|
Bayesian Adaptive Design for Trials with Delayed Binary Outcome Using Historical Control Data
Nusrat Harun, Cincinnati Children's Hospital ; Mi-Ok Kim, Cincinnati Children's Hospital Medical Center; Chunyan Liu, Cincinnati Children's Hospital
9:35 AM
|
Bayesian Analysis of Quantal Bioassay Experiments Incorporating Historical Controls via Bayes Factors
Luis Leon Novelo, The University of Texas Health Science Center at Houston; Andrew Womack, Indiana University; Hongxiao Zhu, Virginia Tech; Xiaowei Wu, Virginia Polytechnic Institute and State University
11:50 AM
|
Application of Propensity-Score Matching in Data Augmentation of Randomized Clinical Trials: A Case Study
Junjing Lin, AbbVie; Margaret Gamalo-Siebers, Eli Lilly and Company; Ram Tiwari, FDA/CDER/OT/OB
2:20 PM
|
Next-Generation Flow Field Forecasting: Organizing and Searching Historical Time Series Data Using CART
Kyle Caudle, South Dakota School of Mines and Technology; Michael Frey, Bucknell University; Patrick Fleming, South Dakota School of Mines and Technology
3:05 PM
|
Optimal Borrowing of Historical Control Data in Clinical Trials
Saurabh Mukhopadhyay, AbbVie; Qi Tang, AbbVie; Alan Hartford, AbbVie
3:20 PM
|
Bayesian Modeling of Phase II Dose-Ranging Clinical Trials
Shu-Yen Ho, PAREXEL
3:35 PM
|
|
Thursday, 08/04/2016
|
Dynamic Weighted Average Approach for Predicting Street Parking Availability
Yi Hua, University of Illinois at Chicago; Ouri E. Wolfson, University of Illinois at Chicago; Xudong Lin, South China Agricultural University; Jie Yang, University of Illinois at Chicago
9:20 AM
|
Covariate-Adjusted Borrowing of Historical Data for Clinical Development
John Zhong, Biogen; Baoguang Han, Biogen; Peng Sun, Biogen; Stacy Lindborg, Biogen; Guochen Song, Quintiles
10:35 AM
|
Utilization of Historical Patient-Level Data for Efficient Trial Design
Zachary Thomas, Eli Lilly and Company; Tianle Hu, Eli Lilly and Company; Nathan Enas, Eli Lilly and Company; Honglu Liu, Eli Lilly and Company
10:55 AM
|
Using Clustered Historical Borrowing in Clinical Trials
Michelle Detry, Berry Consultants; Kert Viele, Berry Consultants
11:15 AM
|
Use of Co-Data in Clinical Trials with Time-to-Event Endpoint
Satrajit Roychoudhury, Novartis
11:35 AM
|
How to Decide When to Borrow Historical Data for a Clinical Trial
Qi Tang, AbbVie; Martin King, AbbVie; Ran Liu, AbbVie; Bo Fu, AbbVie; Sandra Lovell, AbbVie; Alan Hartford, AbbVie
11:55 AM
|
|
|
